Diovan News
ADRs in Focus: Novartis ADRs Decline - Houston Chronicle
Scotcher said generic versions of osteoporosis drug Zometa and bone disease drug Aclasta could go on sale as soon as 2011, and its hypertension drug Diovan ...
BROKERWATCH Novartis cut to 'underweight' vs 'neutral' by HSBC ... - Euro2day
... Aclasta and Exforge treatments and its Tekturna product''s struggle to demonstrate value, having been undermined by cheaper alternatives for Diovan. ...
Pharma Still Taking Baby Steps on the Web - PharmExec.com
For example, Novartis used mobile technology to push its high-blood-pressure treatment Diovan. Novartis placed placards in waiting rooms that encouraged ...
Pharma Still Taking Baby Steps on the Web - PharmExec.com
all 2 news articles
Novartis premium threatened by sparse new drugs - Guardian Unlimited
all 2 news articles
Japan settles for modest changes to pharma pricing system - Pharma Times (subscription)
... Ingelheim/Astellas’ Micardis (telmisartan), Daiichi Sankyo’s Olmetec (olmesartan), Novartis’ Diovan (valsartan) and Takeda’s Blopress (candesartan). ...
Costco program gives uninsured rock bottom drug prices - KING5.com
We compared Costco's prices for five popular drugs - Diovan, Lunesta, Prevacid, Furosemide and Fluoxetine to four other pharmacies.
Novartis posts 45 percent drop - Cay Compass
Analysts had predicted the fourth quarter would be the weakest for Novartis, which makes hypertension drug Diovan and cancer pill Glivec – known as Gleevec ...
Novartis profits hit by restructuring charge - Euro2day
Pharmaceuticals mainstays Diovan for high blood pressure and Glivec for leukaemia also continued to expand sales sharply, for the first time breaching for ...
Novartis blood pressure treatment gets US approval - MarketWatch
Novartis hopes that it will eventually become a multibillion dollar product, and analysts expect it to replace Diovan - the company's current top-seller ...
Diovan RSS Feed